Sugi Predict

Sugi Predict / Compounds / SCHEMBL564889

SCHEMBL564889

SCHEMBL564889

CCOC(=O)C(=CN(C)C)n1ccnn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2C9 P11712 2/20 0.41
▸ MEN1 O00255 5/20 0.34
▸ KMT2A Q03164 5/20 0.34
▸ MAPT P10636 4/20 0.34
▸ ALDH1A1 P00352 2/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ MITF O75030 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ CTDSP1 Q9GZU7 1/20 0.31
▸ USP2 O75604 1/20 0.31
▸ IDE P14735 1/20 0.31
▸ TNNI3 P19429 1/20 0.31
▸ TNNT2 P45379 1/20 0.31
▸ TNNC1 P63316 1/20 0.31
▸ NPSR1 Q6W5P4 3/20 0.31
▸ LMNA P02545 2/20 0.31
▸ CYP1A2 P05177 1/20 0.31
▸ CYP2C19 P33261 1/20 0.31
▸ S1PR4 O95977 1/20 0.31
▸ S1PR1 P21453 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL564888 1.00 CYP2C9 (0.41) CYP2C9MEN1KMT2AMAPTALDH1A1
SCHEMBL4804379 1.00 CYP2C9 (0.41) CYP2C9MEN1KMT2AMAPTALDH1A1
SCHEMBL6114340 0.84 LMNA (0.31) LMNA
SCHEMBL6114336 0.84 LMNA (0.31) LMNA
SCHEMBL15532243 0.79 LMNA (0.35) LMNA
SCHEMBL4751957 0.76 CYP2C9 (0.40) CYP2C9MEN1KMT2AMAPTALDH1A1
SCHEMBL17996197 0.76 CYP2C9 (0.40) CYP2C9MEN1KMT2AMAPTALDH1A1
SCHEMBL17383592 0.76 KMT2A (0.41) CYP2C9MEN1KMT2AMAPTALDH1A1
SCHEMBL16589233 0.76 CYP2C9 (0.45) CYP2C9MEN1KMT2AMAPTALDH1A1
SCHEMBL6784600 0.74 LPO (0.37) KMT2AALDH1A1KDM4ECTDSP1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111825689-B Crystal form of dihydropyrazolone compound and preparation method thereof 中国医药研究开发中心有限公司 2023-05-05 — — CN disclosed
CN-111825690-B Novel crystal form of PHD inhibitor and preparation method thereof 中国医药研究开发中心有限公司 2022-09-27 — — CN disclosed
CN-109694380-B Dihydropyrazolone compound and preparation method and medical application thereof 中国医药研究开发中心有限公司 2022-09-27 — — CN disclosed
CN-111825690-A Novel crystal form of PHD inhibitor and preparation method thereof 中国医药研究开发中心有限公司 2020-10-27 — — CN disclosed
CN-111825689-A Novel crystal form of dihydropyrazolone compound and preparation method thereof 中国医药研究开发中心有限公司 2020-10-27 — — CN disclosed
US-10301289-B2 Method for the preparation of triazole compounds BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-05-28 — — US disclosed
EP-2640718-B1 SUBSTITUTED SODIUM-1H-PYRAZOL-5-OLATE BAYER IP GMBH (DE) 2018-03-28 — — EP disclosed
EP-2847183-B1 PROCESS FOR THE PREPARATION OF TRIAZOLE COMPOUNDS Bayer Pharma AG (DE) 2017-06-21 — — EP disclosed
EP-2383269-B1 Substituted Dihydropyrazolones for the treatment of cardiovascular diseases BAYER IP GMBH (DE) 2017-01-18 — — EP disclosed
US-9533972-B2 Substituted sodium-1H-pyrazole-5-olate BAYER INTELLECTUAL PROPERTY GMBH (DE) 2017-01-03 — — US disclosed
US-8067407-B2 Substituted dihydropyrazolones and their use BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2011-11-29 — — US disclosed
EP-2383269-A2 Substituted Dihydropyrazolones for the treatment of cardiovascular diseases Bayer Pharma AG (DE) 2011-11-02 — — EP disclosed
EP-2265602-A1 SUBSTITUTED DIHYDROPYRAZOLONES AS INHIBITORS OF HIF-PROLYL-4-HYDROXYLASES Bayer Schering Pharma Aktiengesellschaft (DE) 2010-12-29 — — EP disclosed
US-20100305085-A1 SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-12-02 — — US disclosed
US-20100305085-A1 SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-12-02 — — US disclosed
US-20090269420-A1 SUBSTITUTED DIHYDROPYRAZOLONES AND THEIR USE BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-10-29 — — US disclosed
US-20090269420-A1 SUBSTITUTED DIHYDROPYRAZOLONES AND THEIR USE BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-10-29 — — US disclosed
WO-2009129945-A1 SUBSTITUTED DIHYDROPYRAZOLONES AS INHIBITORS OF HIF-PROLYL-4-HYDROXYLASES BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-10-29 — — WO disclosed
EP-2084151-A1 SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HAEMATOLOGICAL DISEASES Bayer HealthCare AG (DE) 2009-08-05 — — EP disclosed
WO-2008067871-A1 SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HAEMATOLOGICAL DISEASES BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-06-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10301289-B2 Method for the preparation of triazole compounds CYP4B1, BRI3BP, BRD4 CYP2C9 461/4885MEN1 819/4885KMT2A 371/4885
US-20090269420-A1 SUBSTITUTED DIHYDROPYRAZOLONES AND THEIR USE GLS, ATP6V1B1, PFKP CYP2C9 2120/4885MEN1 3957/4885KMT2A 3833/4885
US-20100305085-A1 SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HEMATOLOGICAL DISEASES THPO, PFKP, HPGDS CYP2C9 662/4885MEN1 2510/4885KMT2A 1588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.